Men's Health News

RSS

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.

20 Jan 2010

Erectile dysfunction can be strongly related to the development of CVD

In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).

20 Jan 2010

Bone marrow transplantation survivors can father children: new study says

Men who were previously deemed sterile due to aggressive cancer treatments may still be able to biologically father children according to a new study published in the journal, Bone Marrow Transplantation.

18 Jan 2010

Androgen replacement therapy may ward off heart damage, says study

A man's male hormones may ward off heart damage by helping vessels around the heart regenerate, suggest Australian researchers in a report posted January 13 in the Journal of Experimental Medicine (www.jem.org).

18 Jan 2010

European trial casts doubt over the viability of prostate cancer screening

A large European trial has cast doubt over the viability of prostate cancer screening, concluding that one in eight men receive a positive test result when they do not have the disease.

13 Jan 2010

Researchers identify genetic variant linked with the risk of prostate cancer

Researchers at Wake Forest University Baptist Medical Center and colleagues have identified the first genetic variant associated with aggressive prostate cancer, proving the concept that genetic information may one day be used in combination with other factors to guide treatment decisions.

12 Jan 2010

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.

11 Jan 2010

New data from phase 3 study of avanafil for treatment of ED announced

VIVUS, Inc. today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED).

11 Jan 2010

Seminar highlights latest treatment options for common medical conditions that affect men

Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.

8 Jan 2010

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Prostate Cancer

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Prostate Cancer to reflect new recommendations regarding active surveillance, also referred to as watchful waiting, for men with low risk prostate cancer.

8 Jan 2010

Exercise, nutrition and hormone optimization are key to improve men's health issues

Grant Mansell was 46 and frustrated with his 300 pound physique, ensuing back pain, rising cholesterol, dependency on blood pressure medicine but most of all not enjoying life with his wife and children.

8 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Circumcision lowers HIV risk; changes bacterial community on penis microbiome

Circumcision, which substantially lowers HIV risk in men, also dramatically changes the bacterial communities of the penis, according to a study led by scientists at the Translational Genomics Research Institute (TGen) and Johns Hopkins University and published Jan. 6 in the scientific journal PLoS ONE.

5 Jan 2010

Author evaluates potential benefits of IAD for treating prostate cancer

'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

5 Jan 2010

Androgen receptor plays critical role in wound healing

A molecular receptor pivotal to the action of male hormones such as testosterone also plays a crucial role in the body's ability to heal, report scientists in the December issue of the Journal of Clinical Investigation.

5 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Men's Health News

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

Erectile dysfunction can be strongly related to the development of CVD

Bone marrow transplantation survivors can father children: new study says

Androgen replacement therapy may ward off heart damage, says study

European trial casts doubt over the viability of prostate cancer screening

Researchers identify genetic variant linked with the risk of prostate cancer

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

New data from phase 3 study of avanafil for treatment of ED announced

Seminar highlights latest treatment options for common medical conditions that affect men

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Prostate Cancer

Exercise, nutrition and hormone optimization are key to improve men's health issues

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

U.S. market for urological devices to reach over $5.4 billion in 2016

Circumcision lowers HIV risk; changes bacterial community on penis microbiome

Author evaluates potential benefits of IAD for treating prostate cancer

Androgen receptor plays critical role in wound healing

Erectile dysfunction linked to RLS in older men

TRAP-1 may prevent cancer cell death, current research suggests

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News